ReviewThe Journal of clinical investigation2007
On future's doorstep: RNA interference and the pharmacopeia of tomorrow.
Review in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Antisense oligonucleotide against hTERT (Cantide) inhibits tumor growth in an orthotopic primary hepatic lymphoma mouse model.PloS one · 2012Trial
- Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2023Review
- Krüppel-Like Factor 6 Splice Variant 1: An Oncogenic Transcription Factor Involved in the Progression of Multiple Malignant Tumors.Frontiers in cell and developmental biology · 2021Review
- Insight Into the Prospects for RNAi Therapy of Cancer.Frontiers in pharmacology · 2021Review
- Delivery strategies and potential targets for siRNA in major cancer types.Advanced drug delivery reviews · 2016Review
- Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell disease.Clinical and translational medicine · 2016Article
- Article
- Formulation Strategies, Characterization, and In Vitro Evaluation of Lecithin-Based Nanoparticles for siRNA Delivery.Journal of drug delivery · 2012Article
- Vasopressin V2R-targeting peptide carrier mediates siRNA delivery into collecting duct cells.PloS one · 2012Article
- Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference.Cancer gene therapy · 2010Article
- Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.Cardiovascular research · 2010Review
- siRNA-based therapy ameliorates glomerulonephritis.Journal of the American Society of Nephrology : JASN · 2010Article
- The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking.Oligonucleotides · 2010Article
- Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.The Mount Sinai journal of medicine, New York · 2009Review
- Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.Current gene therapy · 2009Review
- Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.Experimental and molecular pathology · 2009Review
- Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy.Investigative ophthalmology & visual science · 2009Article
- Effects of local mRNA structure on posttranscriptional gene silencing.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.The Journal of biological chemistry · 2008Article
- RNA processing and mRNA surveillance in monogenic diabetes.Gene regulation and systems biology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Small molecules and antibodies have revolutionized the treatment of malignant diseases and appear promising for the treatment of many others. Nonetheless, there are many candidate therapeutic targets that are not amenable to attack by the current generation of targeted therapies, and in a small but growing number of patients, resistance to initially successful treatments evolves. This Review Series on the medicinal promise of posttranscriptional gene silencing with small interfering RNA and other molecules capable of inducing RNA interference (RNAi) is motivated by the hypothesis that effectors of RNAi can be developed into effective drugs for treating malignancies as well as many other types of disease. As this Review Series points out, there is still much to do, but many in the field now hope that the time has finally arrived when "antisense" therapies will finally come of age and fulfill their promise as the magic bullets of the 21st century.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.